These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 33619631)

  • 1. Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms.
    Yokokawa A; Kaneko S; Endo S; Minowa Y; Ayukawa H; Hirano R; Nagashima F; Naruge D; Okano N; Kobayashi T; Kawai K; Furuse J; Furuta T; Shibasaki H
    Eur J Drug Metab Pharmacokinet; 2021 Mar; 46(2):317-324. PubMed ID: 33619631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan.
    Ando Y; Ueoka H; Sugiyama T; Ichiki M; Shimokata K; Hasegawa Y
    Ther Drug Monit; 2002 Feb; 24(1):111-6. PubMed ID: 11805731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.
    Wang Y; Shen L; Xu N; Wang JW; Jiao SC; Liu ZY; Xu JM
    World J Gastroenterol; 2012 Dec; 18(45):6635-44. PubMed ID: 23236239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.
    Araki K; Fujita K; Ando Y; Nagashima F; Yamamoto W; Endo H; Miya T; Kodama K; Narabayashi M; Sasaki Y
    Cancer Sci; 2006 Nov; 97(11):1255-9. PubMed ID: 16965601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan.
    van Erp NP; Baker SD; Zhao M; Rudek MA; Guchelaar HJ; Nortier JW; Sparreboom A; Gelderblom H
    Clin Cancer Res; 2005 Nov; 11(21):7800-6. PubMed ID: 16278402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of one-point plasma SN-38G/SN-38 concentration ratios as a substitute for UGT1A1 genetic information after irinotecan administration.
    Hirose K; Yamashita K; Takada H; Kaneda N; Fukami K; Maruo E; Kitamura M; Hasegawa J; Maeda Y
    Int J Clin Oncol; 2014 Apr; 19(2):397-402. PubMed ID: 23605141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of green tea compounds on irinotecan metabolism.
    Mirkov S; Komoroski BJ; Ramírez J; Graber AY; Ratain MJ; Strom SC; Innocenti F
    Drug Metab Dispos; 2007 Feb; 35(2):228-33. PubMed ID: 17108060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
    Innocenti F; Kroetz DL; Schuetz E; Dolan ME; Ramírez J; Relling M; Chen P; Das S; Rosner GL; Ratain MJ
    J Clin Oncol; 2009 Jun; 27(16):2604-14. PubMed ID: 19349540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D.
    Jinno H; Tanaka-Kagawa T; Hanioka N; Saeki M; Ishida S; Nishimura T; Ando M; Saito Y; Ozawa S; Sawada J
    Drug Metab Dispos; 2003 Jan; 31(1):108-13. PubMed ID: 12485959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [FOLFIRINOX for Locally Advanced and Recurrent Pancreatic Cancer with UGT1A1 *6 and or UGT1A1*28 Polymorphisms-A Report of Two Cases].
    Ishigame T; Kimura T; Tsukida S; Suzushino S; Muto M; Sato N; Kofunato Y; Okada R; Kenjo A; Shimura T; Marubashi S
    Gan To Kagaku Ryoho; 2019 Apr; 46(4):754-756. PubMed ID: 31164525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin.
    Han JY; Lim HS; Shin ES; Yoo YK; Park YH; Lee JE; Jang IJ; Lee DH; Lee JS
    J Clin Oncol; 2006 May; 24(15):2237-44. PubMed ID: 16636344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms.
    Suenaga M; Fuse N; Yamaguchi T; Yamanaka Y; Motomura S; Matsumoto H; Hamamoto Y; Mizunuma N; Doi T; Hatake K; Iwasaki J; Ohtsu A
    J Clin Pharmacol; 2014 May; 54(5):495-502. PubMed ID: 24382596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.
    Cecchin E; Innocenti F; D'Andrea M; Corona G; De Mattia E; Biason P; Buonadonna A; Toffoli G
    J Clin Oncol; 2009 May; 27(15):2457-65. PubMed ID: 19364970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetic model of irinotecan and its metabolites in patients with metastatic colorectal cancer.
    Oyaga-Iriarte E; Insausti A; Sayar O; Aldaz A
    Eur J Clin Pharmacol; 2019 Apr; 75(4):529-542. PubMed ID: 30610273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired irinotecan biotransformation in hepatic microsomal fractions from patients with chronic liver disease.
    d'Esposito F; Nebot N; Edwards RJ; Murray M
    Br J Clin Pharmacol; 2010 Sep; 70(3):400-8. PubMed ID: 20716241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
    Mathijssen RH; de Jong FA; van Schaik RH; Lepper ER; Friberg LE; Rietveld T; de Bruijn P; Graveland WJ; Figg WD; Verweij J; Sparreboom A
    J Natl Cancer Inst; 2004 Nov; 96(21):1585-92. PubMed ID: 15523087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients.
    Rouits E; Charasson V; Pétain A; Boisdron-Celle M; Delord JP; Fonck M; Laurand A; Poirier AL; Morel A; Chatelut E; Robert J; Gamelin E
    Br J Cancer; 2008 Oct; 99(8):1239-45. PubMed ID: 18797458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study.
    Umemoto K; Takahashi H; Morizane C; Yamada I; Shimizu S; Shioji K; Yoshida Y; Motoya M; Mizuno N; Kojima Y; Terashima T; Uesugi K; Ueno M; Furuse J; Akimoto T; Ikeda M
    Cancer Chemother Pharmacol; 2021 Mar; 87(3):397-404. PubMed ID: 33386925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of irinotecan metabolism by ketoconazole.
    Kehrer DF; Mathijssen RH; Verweij J; de Bruijn P; Sparreboom A
    J Clin Oncol; 2002 Jul; 20(14):3122-9. PubMed ID: 12118026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX.
    Shirasu H; Todaka A; Omae K; Fujii H; Mizuno N; Ozaka M; Ueno H; Kobayashi S; Uesugi K; Kobayashi N; Hayashi H; Sudo K; Okano N; Horita Y; Kamei K; Yukisawa S; Kobayashi M; Fukutomi A
    Cancer Sci; 2019 Feb; 110(2):707-716. PubMed ID: 30447099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.